We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.
- Authors
Broglio, Fabio; Fubini, Alberto; Morello, Mara; Arvat, Emanuela; Aimaretti, Gianluca; Gianotti, Laura; Boghen, Muny F.; Deghenghi, Romano; Mangiardi, Lucia; Ghigo, Ezio; Ghigo
- Abstract
OBJECTIVEThere is evidence showing that GH and IGF-I have specific receptors in the heart and that these hormones are able to promote cardiac remodelling and inotropism. It has been reported that patients with dilated cardiomyopathy (DCM) benefit from treatment with rhGH showing a striking increase in cardiac contractility. However, until now, the activity of GH/IGF-I axis in DCM has never been clearly assessed. PATIENTSTo clarify this point, we enrolled 39 patients with idiopathic or post-ischaemic DCM (36 M/3 F; age (mean ± S.D.) 55.3 ± 9.0 years; BMI: 25.3 ± 3.2 kg/m2; New York Heart Association class (NYHA) I/2, II/19, III/15, IV/3) and 42 age-matched controls (CS, 38 M/4 F; age 56.0 ± 7.8 years; BMI: 24.9 ± 1.5 kg/m2). DCM patients were characterized by a left-ventricular diastolic diameter of 73.8 ± 8.3 mm, a shortening fraction of 15.9 ± 6.4% and a left ventricular ejection fraction of 25.1 ± 8.7%. In all subjects clinical and biochemical indices of renal and hepatic function as well as nutritional parameters were in the normal range. MEASUREMENTSIn both groups we studied: a) IGF-I levels in basal conditions and after administration of low rhGH doses for 4 days (5.0 or 10.0 μ/kg/day × 4 days); b) the acute GH-response to GHRH (1.0 μ/kg i.v.) or hexarelin (HEX, 2.0 μ/kg i.v.), a peptidyl GH secretagogue (GHRP); c) mean GH concentration (mGHc) over 10 h sampling (every 20 min) from 2200 h to 0800 h. RESULTSBasal IGF-I levels in DCM were lower (P = 0.000039) than in CS (135.2 ± 46.8 vs. 193.7 ± 63.7 μ/l), whereas, basal IGFBP-3 and GHBP2 levels in DCM and CS were similar (2.5 ± 1.3 vs. 2.6 ± 0.5 mg/l and 25.3 ± 3.6 vs. 28.3 ± 5.0%; P = 0.95 and P = 0.085, respectively). After 4 days of 5.0 μ/kg/day rhGH administration, IGF-I levels in DCM (215.4 ± 82.0 μ/l; P = 0.0023 vs. baseline) remained lower (P = 0.027) than those in CS...
- Subjects
SOMATOTROPIN; TREATMENT of cardiomyopathies
- Publication
Clinical Endocrinology, 1999, Vol 50, Issue 4, p417
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1046/j.1365-2265.1999.00696.x